A gene-editing cure for sickle cell is only for teenagers and adults
The core idea stands, but key numbers or details have changed.
TaughtThe CRISPR therapy Casgevy that can functionally cure sickle cell disease was approved for people twelve and older. Young children, who suffer the most damage from the disease early on, were left waiting on the sidelines.
NowOn 1 July 2026 the FDA expanded Casgevy (exagamglogene autotemcel) to children as young as two with severe sickle cell disease or transfusion-dependent beta thalassemia: the first one-time genetic therapy approved for that age group, adding roughly 5,500 eligible children in the US.
What actually happened
This is a genuine moving target: the original 2023 Casgevy approval, already covered in this archive, was itself the milestone that a CRISPR medicine could be approved at all. Two and a half years later the boundary moved again, downward in age, to the patients who arguably need it most, because the strokes, organ damage, and pain crises of sickle cell start in early childhood.
The treatment is still enormous: it means chemotherapy to clear the marrow, then a transplant of the child's own gene-edited stem cells, in specialized centers, at very high cost. So 'updated' is the honest label; the therapy didn't change, its reach did. But 'this cure isn't available to young children' was true in 2025 and is false in 2026.
Newsletter
Get new weekly revisions
Sources
Who was taught this
Still standard through 2026, so anyone who finished school between 1950 and 2026 learned the earlier version.